Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage ...

Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...

(LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better than ...

“The results we got were as good as we can possibly achieve with an oral small molecule GLP-1," says Dr. Dan Skovronsky, ...

Eli Lilly (LLY) stock hits a 52-week low as concerns over its weight-loss drug trial overshadow strong Q2 2025 results. Read ...